Among the largest 'Vertically Integrated' pharmaceutical companies in India, Aurobindo has robust product portfolio spread over major product areas encompassing CVS, CNS, Anti-Retroviral, Antibiotics, Gastroenterologicals, Anti-Diabetics and Anti-Allergic with approved manufacturing facilities by USFDA, UKMHRA, WHO, MCC-SA, ANVISA-Brazil for both APIs & Formulations and has Global presence with own infrastructure, strategic alliances, subsidiaries & joint ventures. Aurobindo’s R & D strengths lie in developing intellectual property in non-infringing processes and resolving complex chemistry challenges. In the process, Aurobindo develops new drug delivery systems, dosage formulations and applies new technology for better processes.
View Top Employees from Aurobindo PharmaWebsite | http://www.aurobindo.com |
Revenue | $2.58 billion |
Employees | 5,593 (5,593 on RocketReach) |
Founded | 1986 |
Phone | +91 40 6672 5000 |
Fax | +91 40 2374 1080 |
Technologies |
JavaScript,
HTML,
PHP
+87 more
(view full list)
|
Industry | Pharmaceuticals, Drug Manufacturing & Research, R&D, Manufacturing Capabilities, Healthcare, Regulatory Approvals |
Keywords | Pharmaceutical Products, Api Manufacturer, Drug Development And Manufacturing |
Competitors | Cipla, Dr Reddy's NZ Ltd, Laurus Labs Limited, Siegfried Holding AG, Sun Farmaceutica do Brasil |
SIC | SIC Code 28 Companies, SIC Code 283 Companies |
NAICS | NAICS Code 32 Companies, NAICS Code 3254 Companies, NAICS Code 32541 Companies, NAICS Code 325 Companies |
Looking for a particular Aurobindo Pharma employee's phone or email?
The Aurobindo Pharma annual revenue was $2.58 billion in 2024.
Sanjay Chaturvedi is the CEO of Aurobindo Pharma.
5,593 people are employed at Aurobindo Pharma.
Aurobindo Pharma is based in Hyderabad, Andhra Pradesh.
The NAICS codes for Aurobindo Pharma are [32, 3254, 32541, 325].
The SIC codes for Aurobindo Pharma are [28, 283].